Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Carcinogens in Blood Pressure Drug Went Undetected for 4 Years

FDA officials report that versions of blood pressure-lowering drug valsartan contained trace amounts of a carcinogen.

Valsartan / Image: Google
Valsartan / Image: Google

Valsartan is an antihypertensive drug used to treat high blood pressure and heart failure. According to a recent USA Today article, some versions of the drug have been tainted with trace amounts of carcinogens linked to cancer that went undetected for years. Investigators believe the root cause of the contamination can be traced back to a change in how the ingredients were made in China and India. The carcinogen detected is nitrosodimethylamine, more commonly known as NDMA, but follow-up testing showed that some batches also contained another carcinogen NDEA.

FDA officials said the risk of cancer for patients who took the tainted drugs is low, but the discovery still prompted a widespread recall. NDMA and NDEA are generally considered low-risk contaminants as they’re found in water, dairy products, and foods like charcoal-grilled meats. They are hard to detect in lab testing, but the FDA has more refined methods of testing that helped uncover the contamination that had been going on for years.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?